Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma
Abstract
BACKGROUND Pemetrexed disodium (Alimta [Eli Lilly and Company, Indianapolis, IN], LY231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. Phase II trials showed single‐agent response rates of 16% and 23% in untreated patients with nonsmall cell lung carcinoma (NSCLC). This study was undertaken to determine the response to pemetrexed disodium given in combination with cisplatin. METHODS Previously untreated patients were eligible if they had Stage IIIB or IV NSCLC, performance status 0, 1, or 2, adequate hematology and biochemistry and bidimensionally measurable lesions. Patients with brain metastases or neuropathy higher than Grade 2 were excluded. Pemetrexed disodium 500 mg/m2 was given over 10 minutes, and cisplatin 75 mg/m2 with hydration and mannitol diuresis was administered on Day 1 of each 21‐day cycle. Dexamethasone 4 mg was taken orally once every 12 hours starting 24 hours before treatment and continuing for 6 doses after treatment. Four patients had detailed pemetrexed disodium pharmacokinetic analysis performed. RESULTS Between May 1998 and June 1999, 31 patients were treated on the study. There were 20 males and 11 females; median age was 60 years (range, 35–75 years); there were 5 Stage IIIB, 26 Stage IV, 26 performance status 0 or 1, and 5 performance status 2. In 29 patients evaluable for response, there were 13 partial responses (PRs; overall response rate [ORR], 95%; confidence interval [CI]: 26–64%) of median duration 6.1 months (1.6–7.8 months). Three of four evaluable patients with performance status 2 achieved PR, and 11 of 24 evaluable Stage IV patients responded (ORR, 45.8% in Stage IV). Eighteen patients died. The median survival rate was 8.9 months (range, 1–15+ months). A total of 160 courses were delivered (median, 6 for both cisplatin and pemetrexed disodium). Grade 3 and 4 anemia was observed in 5 and 1 patients, respectively, and Grade 3 and 4 granulocytopenia in 7 and 4 patients, respectively. Grade 3 nausea and emesis occurred in only 2 patients, Grade 3/4 diarrhea in 3 patients, and 2 patients had Grade 3 motor neuropathy. Nine patients had Grade 2 infections, and there was one case of febrile neutropenia. Pharmacokinetic results showed Cmax, clearance and Vss values to be similar to data from single‐agent pemetrexed disodium given in the same dose. CONCLUSIONS The combination of pemetrexed disodium and cisplatin is active against advanced NSCLC and is a well‐tolerated convenient outpatient regimen. It deserves further study to compare it with other standard regimens for NSCLC. Cancer 2001;92:595–600. © 2001 American Cancer Society.Keywords
This publication has 8 references indexed in Scilit:
- Phase I and Pharmacologic Study of Sequences of Gemcitabine and the Multitargeted Antifolate Agent in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2000
- Clinical and Pharmacokinetic Phase I Study of Multitargeted Antifolate (LY231514) in Combination With CisplatinJournal of Clinical Oncology, 1999
- A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalationCancer Chemotherapy and Pharmacology, 1999
- Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II StudyJournal of Clinical Oncology, 1999
- Review on evidence-based cancer medicineAnnals of Oncology, 1998
- Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overviewAnti-Cancer Drugs, 1995
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Human tumor cloning assays: Applications in clinical oncology and new antineoplastic agent developmentCancer and Metastasis Reviews, 1988